Product Name: Apraglutide
Form: TFA salt
CAS No: 1295353-98-8
Molar Mass: 3765.25
Chemical Formula: C172H263N43O52
Synonyms: FE 203799
Storage: Store at -20℃
Sequence: HGDGSFSDE-{Nle}-{d-Phe}-TILDLLAARDFINWLIQTKITD-NH2
Application:
Apraglutide (CAS: 1295353-98-8) is a synthetic peptide analog of glucagon-like peptide-2 (GLP-2), a hormone involved in the regulation of gastrointestinal function and nutrient absorption. Apraglutide acts as a GLP-2 receptor agonist, stimulating intestinal growth and improving nutrient absorption in the small intestine. It has shown potential therapeutic applications in the treatment of gastrointestinal disorders characterized by intestinal failure, such as short bowel syndrome (SBS). By promoting intestinal growth and function, apraglutide may help reduce dependence on parenteral nutrition and improve overall nutritional status in patients with SBS. Clinical trials have demonstrated the efficacy and safety of apraglutide in increasing intestinal absorption, reducing diarrhea, and improving quality of life in patients with SBS. However, further research is needed to optimize dosing regimens, evaluate long-term safety, and explore additional therapeutic indications for apraglutide.
Current Research:
Apraglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed for the treatment of type 2 diabetes (T2D). It is designed to enhance the insulin secretion in response to meals, while also suppressing glucagon release and reducing gastric emptying, which helps in controlling blood glucose levels. Apraglutide offers significant advantages over other GLP-1 agonists, primarily due to its extended duration of action, which allows for less frequent dosing.
Mechanism of Action
Apraglutide works by mimicking the action of the natural GLP-1 hormone, a peptide secreted by the intestines in response to food intake. GLP-1 plays a crucial role in regulating glucose metabolism by:
Enhancing Insulin Secretion: GLP-1 promotes the release of insulin from pancreatic beta cells in a glucose-dependent manner. This means insulin is released when blood sugar levels are high, helping to lower those levels after meals.
Inhibiting Glucagon Secretion: Glucagon is a hormone that increases blood sugar by stimulating the liver to release stored glucose. GLP-1 inhibits glucagon secretion, which helps prevent excess glucose production by the liver.
Slowing Gastric Emptying: By slowing the rate at which food leaves the stomach, apraglutide helps with postprandial glucose control. This also contributes to a sense of fullness, which may help with weight loss or weight management, a significant benefit for many patients with type 2 diabetes.
Promoting Satiety: GLP-1 agonists like apraglutide can also help reduce appetite, leading to potential weight loss. This is an important aspect of managing type 2 diabetes, as obesity is a major risk factor for the development and progression of the disease.
Apraglutide is designed to have a long half-life, which allows it to be administered once-weekly. This extended action reduces the need for frequent injections compared to other GLP-1 agonists, which typically require daily or weekly dosing.
Clinical Applications
Apraglutide has been primarily investigated for the treatment of type 2 diabetes (T2D), a condition characterized by insulin resistance and impaired insulin secretion. It is used to lower blood glucose levels and improve glycemic control, either as a monotherapy or in combination with other antidiabetic drugs, such as metformin, sulfonylureas, or insulin.
The ability of apraglutide to help with weight management is another key feature, as weight gain often complicates the management of T2D. Many patients with T2D are overweight or obese, and weight reduction is an important therapeutic goal. Apraglutide’s satiety-inducing properties are beneficial in this context, making it a viable treatment option for patients who struggle with weight management.
Apraglutide is also being explored for its potential benefits in patients with cardiovascular disease (CVD) and chronic kidney disease (CKD). There is growing evidence that GLP-1 receptor agonists can improve cardiovascular outcomes in people with type 2 diabetes, including reducing the risk of heart attacks, strokes, and hospitalization for heart failure.
Advantages Over Other GLP-1 Agonists
Long-Acting Effect: One of the primary advantages of apraglutide over other GLP-1 agonists is its extended duration of action, allowing for once-weekly injections. This is more convenient for patients compared to other GLP-1 agonists, which often require daily or weekly injections.
Improved Glycemic Control: Apraglutide has demonstrated potent blood sugar-lowering effects in clinical trials. It helps lower HbA1c (a marker of long-term blood glucose control) effectively and has been shown to achieve statistically significant reductions in both fasting blood glucose and postprandial glucose levels.
Weight Loss: As mentioned, weight management is a crucial component in managing type 2 diabetes, and apraglutide’s ability to promote weight loss is a significant benefit. It can reduce body weight through its effects on satiety and caloric intake, which could help with the management of comorbidities like obesity.
Cardiovascular Protection: Like other GLP-1 receptor agonists, apraglutide may provide cardiovascular benefits, including reducing the risk of heart attacks, stroke, and heart failure hospitalizations. This is particularly relevant for patients with type 2 diabetes, as they are at high risk for cardiovascular diseases.
Renal Protection: Studies have also suggested that GLP-1 receptor agonists, including apraglutide, may offer renal protection, particularly in patients with diabetes and chronic kidney disease (CKD). This potential benefit is important as kidney disease is a major complication of diabetes.
Clinical Trials and Efficacy
Clinical trials of apraglutide have demonstrated its efficacy in improving glycemic control and promoting weight loss in people with type 2 diabetes. In Phase 2 and Phase 3 trials, apraglutide has shown significant reductions in HbA1c levels compared to placebo and other glucose-lowering therapies. These studies have also highlighted its well-tolerated profile, with patients reporting few side effects.
In addition to its glucose-lowering effects, apraglutide has shown promise in achieving significant weight loss, a common and often challenging aspect of diabetes management. Early-stage trials have demonstrated that patients treated with apraglutide experienced greater weight reductions compared to those on other GLP-1 receptor agonists or standard treatments.
Furthermore, ongoing studies are investigating apraglutide’s potential cardiovascular and renal benefits. Preliminary results suggest that, like other GLP-1 receptor agonists, apraglutide may help reduce the risk of cardiovascular events and protect kidney function in patients with diabetes-related complications.
Safety and Tolerability
Apraglutide has been generally well tolerated in clinical trials, with the most common adverse effects being gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. These side effects are typically mild to moderate and tend to decrease over time as the body adapts to the medication.
Because apraglutide is a long-acting GLP-1 agonist, it is less likely to cause the more severe hypoglycemic episodes that can occur with other types of diabetes medications, such as insulin or sulfonylureas, especially when used alone. However, there is a risk of hypoglycemia when combined with other insulin secretagogues or insulin.
Pancreatitis and gallbladder disease are potential concerns with all GLP-1 receptor agonists, including apraglutide. Although these side effects are rare, patients with a history of pancreatitis or gallbladder issues should use caution when considering treatment with apraglutide.
Future Directions
Research on apraglutide is ongoing, with future studies focusing on its long-term safety, cardiovascular benefits, and renal effects. Additionally, studies are exploring its potential use in combination with other treatments for type 2 diabetes, such as SGLT2 inhibitors, to further enhance glycemic control and reduce the risk of complications.
There is also interest in investigating once-weekly apraglutide in other conditions, such as pre-diabetes or obesity management, where weight loss and insulin sensitivity are primary therapeutic goals.
Conclusion
Apraglutide represents a promising advancement in the treatment of type 2 diabetes. Its ability to effectively control blood glucose, promote weight loss, and provide potential cardiovascular and renal protection makes it a highly beneficial therapy for patients with diabetes. The convenience of once-weekly dosing adds to its appeal, improving patient compliance and quality of life. As research progresses, apraglutide may emerge as a key treatment option in the management of type 2 diabetes and its associated complications.
Reference:
Get a Quote
LinkPeptide
